News|Videos|May 15, 2026

MAD-ID and SIDP Launching a New Conference Named Antimicrobials

Fact checked by: Justin Mancini

Leaders from SIDP and MAD-ID highlighted their new partnership and announced the launch of the Antimicrobials meeting in 2027, focused on combining cutting-edge science with clinical antimicrobial practice.

A new collaboration between the Society of Infectious Diseases Pharmacists (SIDP) and Making a Difference in Infectious Diseases (MAD-ID) is set to reshape the future of antimicrobial education and pharmacotherapy meetings.

During the discussion, leaders from both organizations described the partnership as a natural evolution built on shared missions centered on antimicrobial stewardship, pharmacotherapy, and advancing infectious diseases education. The collaboration will culminate in the launch of a new conference, Antimicrobials, from May 22 to 26, 2027, in Baltimore, Maryland.

SIDP President Erin McCreary, PharmD, BCIDP, FIDSA, highlighted the broad educational scope and collaborative vision behind the new event.

“There’s going to be clinical infectious diseases, antimicrobial stewardship, PK/PD [pharmacokinetics/pharmacodynamics], drug development pipeline antibiotics, and really how those all play in pharmacotherapy, which is really our heart and soul,” she said.

Michael J. Rybak, PharmD, PhD, MPH, FCCP, FIDP, president and treasurer of MAD-ID, emphasized the meeting’s goal of bridging existing gaps in infectious diseases conferences.

“We hope to split the two and have both clinical applications and the latest science, again advancing therapeutics, as Erin has mentioned, and optimizing antimicrobial therapy.”

The meeting will also feature partnerships with the ESCMID PKPD Study Group and the International Society of Anti-Infective Pharmacology, including a dedicated PK/PD workshop. Organizers said the strong turnout during the first year of the SIDP and MAD-ID collaboration exceeded expectations, with more than 800 participants attending through workshops, virtual programming, and in-person sessions.

As this is breaking news, stay tuned for more official information as it becomes available in the coming weeks.


Related to this article

IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures
Staphylococcus aureus Bacteremia (SAB) causes significant morbidity and globally is the leading cause of death from bloodstream infection. This month, the IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.
How The Food Safety Surveillance Infrastructure Works in the US
In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.